Clinical Research, Pharma & Healthcare FinancingKiromic BioPharma Reports 10-Month Progression-Free SurvivalBusiness WireFebruary 19, 2025February 20, 2025 by Business WireFebruary 19, 2025February 20, 202509 Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its...